Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMAW) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 24,488 shares, a growth of 614.1% from the June 15th total of 3,429 shares. Based on an average daily volume of 51,673 shares, the days-to-cover ratio is currently 0.5 days.

Humacyte Stock Performance

Shares of NASDAQ HUMAW traded up $0.00 during mid-day trading on Friday, reaching $0.01. 23,667 shares of the company were exchanged, compared to its average volume of 18,246. The company’s 50-day simple moving average is $0.04 and its 200-day simple moving average is $0.08. Humacyte has a twelve month low of $0.00 and a twelve month high of $0.60.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.